- Race Information
- Friends for the Cure Fundraising
- Breast Cancer Survivors
- Participant Center
- I AM KOMEN®
- Photo Gallery
- Brainerd Lakes Race for the Cure®
- Brainerd Lakes Race for the Cure- Registration
- Brainerd Lakes Race for the Cure- Information
- Brainerd Lakes- Teams
- Brainerd Lakes- Survivors
- Brainerd Lakes- Make a Donation
- Brainerd Lakes- 5K Race Results
- Brainerd Lakes- Volunteer
- Brainerd Lakes- Honorary Chairs
- Brainerd Lakes- Sponsors
- Brainerd Lakes- About Us
- Ginger Brauer Award
- Shop for the Cure
Breast Cancer Stories- Join us here as we continue to share stories that celebrate the women and men who inspire us all!
Rally for the Cure - Golf, tennis, dinner events and so much more...
Go Passionately Pink to help save lives! — Just wear pink, have fun and raise money to fight breast cancer. Be inspired by the multitude of ideas right here, or think of your own. There are so many creative ways to have fun and fight breast cancer.
SUSAN G. KOMEN®-FUNDED RESEARCH SHOWS PROMISE IN SLOWING, STOPPING METASTATIC BREAST CANCER
Work Led by Komen-Funded Young Investigator Reveals More about Role of RAGE in Breast Cancer Metastasis
September 29, 2016 – A research grant awarded by Susan G. Komen in 2015 is breaking new ground in the understanding of metastatic breast cancer. Dr. Barry I. Hudson, cancer researcher at Sylvester Comprehensive Cancer Center (part of UHealth – the University of Miami Health System), and team found that blocking expression of Receptor for Advanced Glycation End-products (RAGE) in breast cancer cells led to a decrease in the cells’ ability to invade surrounding tissue. They also showed in both human cells and mouse models that blocking RAGE decreased tumor growth and reduced tumor angiogenesis (development of new blood vessels). In addition, blocking RAGE also reduced the recruitment of inflammatory cells and dramatically decreased metastasis to both the lungs and liver in mouse models of breast cancer.
These data demonstrate that RAGE drives tumor progression and metastasis, and may represent a novel target for the development of new therapies for metastatic breast cancer.
“To achieve our organization’s new Bold Goal to decrease the current number of breast cancer deaths by 50 percent in the U.S. over the next decade, we need significant breakthroughs in the treatment of metastatic breast cancer. The work of Dr. Hudson and his team is an important step to take on the form of the disease that claims 40,000 lives annually,” said Komen President and CEO Dr. Judy Salerno.
“These significant findings also underscore the need for continuous support of research funding for young investigators hoping to launch a career in breast cancer research, like Dr. Hudson, who received a Career Catalyst Research grant last year. The next generation of breast cancer researchers will be the ones to bring us the cures, and we must ensure they are able to pursue their work,” Dr. Salerno added.
Komen recently announced $32.7 million in new research funding, nearly 40 percent of which is focused on metastatic research. To date, the organization has invested more than $166 million in over 400 research grants and more than 40 clinical trials focused on metastatic breast cancer.
Read more about the new findings in Oncogene.
SUSAN G. KOMEN SETS BOLD GOAL TO REDUCE U.S. BREAST CANCER DEATHS BY 50 PERCENT IN 10 YEARS
Plan Targets Health Equity for All, Enhanced Research Focus for Most Lethal Breast Cancers
Sept.13, 2016 – The Susan G. Komen breast cancer organization announced a bold plan today to reduce the nation’s 40,000 breast cancer deaths by 50 percent in 10 years, by improving access to quality and timely cancer care for the underserved and enhancing Komen’s research focus on lethal breast cancers.
“We know that people die of breast cancer for two reasons: a lack of high-quality breast cancer care accessible to everyone, and a lack of treatments for the most aggressive and deadly forms of this disease,” said Dr. Judith A. Salerno, president and CEO of Susan G. Komen. “We are taking direct action designed to solve these problems to reduce breast cancer deaths by half in the U.S. within the next decade.”
$27 Million Advanced for Health Equity
Salerno said today that Fund II Foundation made a grant worth approximately $27 million for a program initially targeting 10 metropolitan areas to significantly reduce what she called the “appalling” difference in death rates between African-American and white women. African-American women are nearly 40 percent more likely to die of breast cancer than white women; in some cities, that gap is as high as 74 percent.
“This constitutes a public health crisis that must be addressed, first in the cities where these death rates are highest, and then in all areas of the country,” Salerno said.
Salerno thanked Fund II Foundation for the grant that makes the initiative possible. “The generosity of Fund II Foundation will save lives,” Salerno said. “We are humbled by the faith that Fund II Foundation has placed in this initiative and its interest in ensuring health equity for African-American citizens.”
Fund II Foundation President, Robert F. Smith said, "No longer should African-American women be more likely to die from a breast cancer diagnosis than others. Through this grant supporting Susan G. Komen, Fund II Foundation will help address these unfair disparities across our country."
Komen’s African-American Health Equity Initiative targets cities where mortality rates and late-stage diagnosis of African-American women are highest. The goal: to reduce the mortality gap by 25 percent within five years of beginning work in each city.
The initial targeted cities are Memphis, Tenn., St. Louis, Mo., Dallas, Los Angeles, Virginia Beach, Va., Atlanta, Chicago, Houston, Washington, D.C. and Philadelphia. Baltimore and Detroit have been identified as high-priority areas as the program expands over the next year.
The African-American Health Equity Initiative supplements the work that Komen and its network of 100 U.S. Affiliates already are doing to remove barriers to cancer care. Komen and Komen Affiliates support thousands of local programs that provide screenings, treatment assistance, emergency financial aid, medical supplies and living expense for underserved individuals.
The organization has invested more than $2 billion over 34 years for these programs aimed at uninsured, under-insured, and medically vulnerable populations.
“We will never waver from our commitment to remove barriers of language, geography, economics or culture for all people facing this disease. Every woman or man must be able to access and receive high-quality breast health and breast cancer care, be supported through their treatment and into survivorship,” Salerno said.
The second prong of Komen’s plan enhances Komen’s focus on aggressive forms of breast cancer and metastatic disease (stage IV or cancer that has spread to other parts of the body).
As the largest nonprofit funder of breast cancer research (investing more than $920 million since inception), Komen has funded nearly $160 million in metastatic disease research since its founding. Komen has funded another $110 million in research on aggressive forms of breast cancer – such as triple negative, inflammatory breast cancer and hormone-positive forms of breast cancer – that are resistant to standard treatments.
“The majority of breast cancer deaths are from metastatic breast cancer. We also know that aggressive forms of breast cancer are more likely to recur and spread, so we are focusing our efforts in both of these areas,” Salerno said.
The new initiative aims to advance research into new treatments for aggressive and metastatic disease. Komen also will seek to leverage next-generation technology that can detect breast cancer at its very earliest stages to prevent recurrence and metastasis.
Progress to Date
Salerno said Komen’s bold goal builds on the progress of the breast cancer movement since Komen was founded in 1982. “Death rates from breast cancer have declined by 37 percent since 1990. We have more treatments than at any time in our history. We’ve come a very long way from a time when breast cancer couldn’t be discussed publicly. Our new bold goal requires us to take a deeper dive and stretch further to ensure that every woman or man can be told, ‘There is help and hope for you.’”
About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $920 million in research and provided more than $2 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 30 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.
About Fund II Foundation
Fund II Foundation makes grants to 501(c)(3) public charities in five areas: 1) preservation of the African-American experience, 2) safeguarding human dignity by giving a voice to the voiceless and promoting human rights 3) improving environmental conservation and providing outdoor education that enables people of all ages and backgrounds to enjoy the numerous benefits of the great outdoors 4) facilitating music education, particularly in primary and secondary schools, to nourish both the mind and the soul 5) and sustaining the uniquely American values of entrepreneurship, empowerment, innovation and security. For more information on Fund II Foundation, visit www.fund2foundation.org.
50 in 10: Susan G. Komen’s Bold Goal for Shaping History and Saving Lives. This publication explains our Goal and how we will achieve it in greater detail, and also shows how the past 35 years of progress have led us to this point.